STOX2

Across TCGA pan-cancer cohorts, STOX2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STOX2 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher STOX2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated STOX2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, ESCA, and COAD are the cancer types where STOX2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.964	0.825	.008	22	view →
ESCA	DFS	Median	All	0.161	0.540	.001	18	view →
COAD	OS	Median	II,III,IV	0.588	0.857	.012	17	view →
PAAD	OS	Median	All	0.112	0.640	.016	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STOX2–UCEC (DFS)

Open the UCEC breakdown →